AVITA Medical, a leading therapeutic acute wound care company, announced it has received the CE Mark under the European Union Medical Device Regulation (EU MDR) for RECELL GO. This allows the Company to commercialise RECELL GO in Europe and in other markets that recognise the CE Mark.

“CE Mark for RECELL GO is an important milestone for AVITA Medical and for patients,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “It enables us to bring this option to burn centres and clinicians in Europe to support their treatment of patients with acute wound injuries.”

RECELL GO is a point-of-care device used by healthcare professionals to prepare a suspension of a patient’s own skin cells (Spray-On Skin™ Cells) from a small sample of healthy skin. The cells are used to promote healing in burns, traumatic, or surgical wounds. RECELL GO builds on the RECELL System, which is already in use across Europe.

Data recently presented at the 2025 European Burns Association Congress demonstrated that adults with deep partial-thickness (second-degree) burns treated with RECELL experienced a 36 per cent reduction in hospital stays compared with traditional grafting, underscoring the clinical value of the RECELL technology.

With the CE Mark secured, AVITA Medical will begin commercialisation of RECELL GO in select European countries, including Germany, Italy, and the United Kingdom, in collaboration with burn centres and clinical partners.